Loading...

Purified anti-mouse CD28 Antibody

Pricing & Availability
Clone
37.51 (See other available formats)
Regulatory Status
RUO
Other Names
Tp44, T44
Isotype
Syrian Hamster IgG
Ave. Rating
Submit a Review
Product Citations
publications
37.51
C57BL/6 splenocytes stained with 37.51 PE and CD3 FITC
  • 37.51
    C57BL/6 splenocytes stained with 37.51 PE and CD3 FITC
Compare all formats
Cat # Size Price Quantity Check Availability Save
102101 50 µg 44€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
102102 500 µg 102€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

CD28 is a 44 kD glycoprotein, also known as Tp44 or T44. It is a member of the Ig superfamily, expressed on thymocytes, most peripheral T cells, and NK cells. In association with CD80 (B7-1) and CD86 (B7-2), CD28 acts as the second signal for T and NK cell activation and proliferation. The 37.51 antibody has been reported to augment in vitro T cell proliferation and cytokine production, and promote CTL development.

Product Details
Technical Data Sheet (pdf)

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Syrian Hamster
Immunogen
C57BL/6 mouse T-cell lymphoma EL-4
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography.
Concentration
0.5 mg/ml
Storage & Handling
The CD28 antibody solution should be stored undiluted between 2°C and 8°C.
Application

FC - Quality tested
IP, IHC-F, Costim, Block - Reported in the literature, not verified in house
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤1.0 µg per million cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.

Application Notes

Additional reported applications (for the relevant formats) include: immunoprecipitation1, in vitro costimulation of T and NK cells1, in vitro blocking of allogeneic mixed leukocyte response and inhibition of MHC-unrestricted CTL cytotoxicity3,4, in vitro induction of thymocyte differentiation2,5-9,11, and immunohistochemical staining of acetone-fixed frozen sections. For in vivo studies or highly sensitive assays, we recommend Ultra-LEAF™ purified antibody (Endotoxin < 0.01 EU/µg, Azide-Free, 0.2 µm filtered) (Cat. No. 102116).

Application References
  1. Gross JA, et al. 1992. J. Immunol. 149:380. (IP, Costim)
  2. Cibotti R, et al. 1997. Immunity 6:245. (Costim)
  3. Masten BJ, et al. 1997. Am. J. Respir. Cell Mol. Biol. 16:335. (Block)
  4. Nishio M, et al. 1996. J. Immunol. 157:4347. (Block)
  5. Zhang N and He Y-W, 2005. J. Exp. Med. 202:395. (Costim)
  6. Terrazas LI, et al. 2005. Intl. J. Parasitology. 35:1349. (Costim)
  7. Perchonock CE, et al. 2006. Mol Cell Biol. 26(16):6005. (Costim)
  8. Wang W, et al. 2007. J. Immunol. 178:4885. (Costim)
  9. Pua HH, et al. 2007. J. Exp. Med. 204:25. (Costim)
  10. Perchonock CE, et al. 2007. J. Immunol. 179:1768.
  11. Barbi J, et al. 2007. Blood 110:2215.
  12. Milpied P, et al. 2011. Blood 118:2993. PubMed
  13. Cunningham NR, et al. 2011. Int Immunol. 23:693. PubMed
  14. Crispin JC, et al. 2012. J. Immunol. 188:3567. PubMed
  15. Li CR, et al. 2014. J Immunol. 192:1425. PubMed
  16. Blankenhaus B, et al. 2014. PLoS Pathog. 10:1003913. PubMed
Product Citations
  1. Kim K, et al. 2016. PLoS One. 11: 0148576. PubMed
  2. Sandu I, et al. 2020. Nat Commun. 11:4454. PubMed
  3. Garo LP, et al. 2021. Nat Commun. 12:2419. PubMed
  4. Tian J, et al. 2021. Autophagy. 17:2586. PubMed
  5. Collin R, et al. 2020. J Immunol. 205:133. PubMed
  6. Campisi L, et al. 2022. Nature. 606:945. PubMed
  7. Halin C, et al. 2022. EMBO J. 41:e111528. PubMed
  8. Liu W, et al. 2022. Stem Cells Int. 2022:1052166. PubMed
  9. Zhu M, et al. 2022. Front Immunol. 13:1019248. PubMed
  10. Kasuya T, et al. 2023. Sci Rep. 13:1653. PubMed
  11. Kuehm LM, et al. 2021. Cancer Immunol Res. 9:227. PubMed
  12. Khojandi N, et al. 2021. Cancer Immunol Res. 9:214. PubMed
  13. Li T, et al. 2022. J Leukoc Biol. 112:845. PubMed
  14. Robles-Valero J, et al. 2022. Mol Oncol. 16:3533. PubMed
  15. Kim H, et al. 2023. Bone Res. 11:17. PubMed
  16. Anto NP, et al. 2023. Front Immunol. 14:1126464. PubMed
  17. Aydin S, et al. 2023. Nat Commun. 14:3106. PubMed
  18. Akiyama C, et al. 2019. J Immunol. 203:835. PubMed
  19. Komuczki J, et al. 2019. Immunity. 50:1289. PubMed
  20. Oh H, et al. 2017. Immunity. 47:450. PubMed
  21. Wiesner DL, et al. 2020. Cell Host Microbe. 614:27. PubMed
  22. Khan KA, et al. 2020. NPJ Breast Cancer. 6:29. PubMed
  23. Cross EW, et al. 2019. PLoS One. 14:e0211446. PubMed
  24. Krovi SH, et al. 2019. Proc Natl Acad Sci U S A. 116:22252. PubMed
  25. Hawse WF, et al. 2019. J Immunol. 203:2771. PubMed
  26. Uzhachenko RV, et al. 2021. Cell Reports. 35(1):108944. PubMed
  27. Zhang Z, et al. 2020. J Immunol. 204:3400. PubMed
  28. Xu ZH, et al. 2021. Mediators Inflamm. 2021:8856326. PubMed
  29. Busnelli M, et al. 2022. Arterioscler Thromb Vasc Biol. 42:839. PubMed
  30. Yamada T, et al. 2019. J Immunol. 202:1088. PubMed
  31. Liang J, et al. 2017. Nat Commun. 8:15732. PubMed
  32. He N 2005. J Immunol. 174:6967. PubMed
  33. Crispin J, et al. 2012. J Immunol. 188:3567. PubMed
  34. Milpied P, et al. 2011. Blood. 118:2993. PubMed
  35. Sanctuary MR, et al. 2019. Mucosal Immunol. 0.638888889. PubMed
  36. Rasoulouniriana D, et al. 2019. J Clin Invest. 129:4151. PubMed
  37. Oghumu S, et al. 2019. J Immunol. 203:789. PubMed
  38. Lu SX, et al. 2021. Cell. . PubMed
  39. Joseph R, et al. 2021. Br J Cancer. 125:176. PubMed
  40. Macchi C, et al. 2022. iScience. 25:104435. PubMed
  41. Kitamura T, et al. 2018. Front Immunol. 8:2004. PubMed
  42. Marangoni F, et al. 2021. Cell. . PubMed
  43. Blankenhaus B, et al. 2014. PLoS Pathog. 10:1003913. PubMed
  44. Anastasiou M, et al. 2021. JCI Insight. 6:. PubMed
  45. Jiang P, et al. 2021. Nat Methods. 18:1181. PubMed
  46. Zhang Z, et al. 2021. Oncoimmunology. 10:1912472. PubMed
  47. Tritama E, et al. 2018. Hum Vaccin Immunother. 14:1524. PubMed
  48. Montes de Oca M, et al. 2020. PLoS Pathog. 16:e1008994. PubMed
  49. Kölle J, et al. 2022. iScience. 25:104440. PubMed
  50. Sekiya T et al. 2018. Cell reports. 24(6):1627-1638 . PubMed
  51. Shimokawa C et al. 2017. Immunity. 46(5):863-874 . PubMed
  52. Tuzlak S, et al. 2017. Cell Death Differ. 24:523. PubMed
  53. Doorduijn EM, et al. 2018. Front Immunol. 0.416666667. PubMed
  54. Rao TN, et al. 2020. J Immunol. 204:2600. PubMed
  55. Khan KA, et al. 2020. NPJ Breast Cancer. 6:29. PubMed
  56. Perchonock C, et al. 2006. Mol Cell Biol . 26:6005. PubMed
  57. Zhang P, et al. 2022. BMC Med. 20:435. PubMed
  58. Srey MT, et al. 2020. PLoS Negl Trop Dis. 14:e0008842. PubMed
  59. Hanoteau A, et al. 2019. J Immunother Cancer. 7:10. PubMed
  60. Xu L et al. 2017. Immunity. 47(3):538-551 . PubMed
  61. McCully M, et al. 2015. J Immunol. 195: 96 - 104. PubMed
  62. Takushi SE, et al. 2020. Hum Gene Ther. 31:626. PubMed
  63. Mao FY, et al. 2021. Cell Mol Gastroenterol Hepatol. 12:395. PubMed
  64. Imani J, et al. 2021. JCI Insight. 6:. PubMed
  65. Xie D, et al. 2020. Eur J Immunol. 50:1729. PubMed
  66. Morales-Mantilla DE, et al. 2022. Elife. 11:. PubMed
  67. Rosenberger C, et al. 2008. Proc Natl Acad Sci U S A. 105:2544. PubMed
  68. Racioppi L, et al. 2019. Nat Commun. 10:2450. PubMed
  69. Miret JJ, et al. 2019. J Immunother Cancer. 7:32. PubMed
  70. Palazon A, et al. 2017. Cancer Cell. . 10.1016/j.ccell.2017.10.003. PubMed
  71. Sharma M, et al. 2020. Circ Res. 127:335. PubMed
  72. Otsuka S, et al. 2021. J Clin Invest. 131:. PubMed
  73. Scholz T, et al. 2017. PLoS One. 12:e0182646. PubMed
  74. Lee JY, et al. 2018. Front Immunol. 0.678472222. PubMed
  75. Samanta D, et al. 2020. Cell Rep. 108073:32. PubMed
  76. Hollmann C, et al. 2016. J Immunol. 197: 3130 - 3141. PubMed
  77. Li Z, et al. 2021. MBio. 12:e0254221. PubMed
  78. Zhang S, et al. 2021. Front Immunol. 12:635076. PubMed
  79. Thumkeo D, et al. 2020. Sci Adv. 6:eaay2432. PubMed
  80. Simula L et al. 2018. Cell reports. 25(11):3059-3073 . PubMed
  81. Hao Y, et al. 2018. Front Immunol. 9:1127. PubMed
  82. Endo Y, et al. 2015. Cell Rep. 12: 1042-1055. PubMed
  83. Sripada A, et al. 2021. PLoS Biol. 19:e3001063. PubMed
  84. Shiozawa S, et al. 2022. iScience. 25:103537. PubMed
  85. Wu Y, et al. 2021. J Clin Invest. 131:. PubMed
  86. Schreiber K, et al. 2020. Cancer Immunol Res. 8:192. PubMed
  87. Katagiri T, et al. 2019. Mucosal Immunol. 12:p1104. PubMed
  88. Majchrzak K, et al. 2017. JCI Insight. 2:e90547. PubMed
  89. Patterson AR, et al. 2019. J Allergy Clin Immunol. 143:245. PubMed
  90. Klein JC, et al. 2017. Nat Commun. 8:14600. PubMed
  91. Lee J, et al. 2020. Cells. 9:. PubMed
  92. Pan S, et al. 2021. Front Cell Dev Biol. 9:629306. PubMed
  93. Schiering C, et al. 2017. Nature. 542:242. PubMed
  94. Fernández-Orth J, et al. 2020. Eur J Immunol. . PubMed
  95. Kiuchi M, et al. 2021. J Exp Med. 218:. PubMed
  96. Link MA, et al. 2017. PLoS One. 12:e0184320. PubMed
  97. Guo J, et al. 2020. Cell Mol Immunol. 1222:17. PubMed
  98. Sun Y, et al. 2021. Nat Commun. 12:5147. PubMed
  99. Rosenberg J, et al. 2020. Cell Systems. 10(5):433-444. PubMed
  100. Stelekati E, et al. 2018. Cell Rep. 2.445833333. PubMed
  101. Niven J, et al. 2019. Cell Rep. 28:21. PubMed
  102. Nakazawa Y, et al. 2021. Elife. 10:. PubMed
  103. Cohen MA, et al. 2020. Cell Stem Cell. 26(4):579-592. PubMed
  104. He N 2005. J Exp Med. 202:395. PubMed
  105. Cunningham N, et al. 2011. Int Immunol. 1.439583333. PubMed
  106. He Y, et al. 2021. eLife. 10:00. PubMed
  107. Wang J, et al. 2021. Am J Cancer Res. 11:2005. PubMed
  108. Perchonock C, et al. 2007. J Immunol. 179:1768. PubMed
  109. Abe Y, et al. 2017. Biochem Biophys Rep. 0.543055556. PubMed
  110. Li C, et al. 2014. J Immunol. 192:1425. PubMed
  111. Robles-Valero J, et al. 2021. EMBO J. 40:e108125. PubMed
  112. Wang W, et al. 2022. Nat Commun. 13:4495. PubMed
  113. Galeano Nio JL, et al. 2020. eLife. 9:00. PubMed
  114. Plaza-Sirvent C, et al. 2017. Cell Rep. 18(1):12-22. PubMed
  115. Bessell CA, et al. 2020. JCI Insight. 5:. PubMed
  116. Chen YH, et al. 2022. Arthritis Res Ther. 24:27. PubMed
  117. Xia L, et al. 2021. Cancer Immunol Res. 9:707. PubMed
  118. Grinberg–Bleyer Y, et al. 2017. Cell. 170:1096. PubMed
RRID
AB_312866 (BioLegend Cat. No. 102101)
AB_312866 (BioLegend Cat. No. 102102)
Disclaimer

This product may be used for research purposes only. It is not licensed for resale and may only be used by the buyer. This product may not be used and is not licensed for clinical assays where the results of such assays are provided as a diagnostic service. If a diagnostic or therapeutic use is anticipated then a license must be requested from the University of California. The availability of such diagnostic and therapeutic use license(s) cannot be guaranteed from the University of California.

Antigen Details

Structure
Ig superfamily, 44 kD
Distribution

Thymocytes, CD4+, CD8+ peripheral T cells, NK cells

Function
Costimulates T and NK cells
Ligand/Receptor
CD80 (B7-1), CD86 (B7-2)
Cell Type
NK cells, T cells, Thymocytes, Tregs
Biology Area
Costimulatory Molecules, Immunology
Molecular Family
CD Molecules
Antigen References

1. Barclay AN, et al. 1997. The Leukocyte Antigen FactsBook Academic Press.
2. Lenschow DJ, et al. 1996. Annu. Rev. Immunol. 14:233.
3. Gross JA, et al. 1992. J. Immunol. 149:380.

Gene ID
12487 View all products for this Gene ID
Specificity (DOES NOT SHOW ON TDS):
CD28
Specificity Alt (DOES NOT SHOW ON TDS):
CD28
App Abbreviation (DOES NOT SHOW ON TDS):
FC,IP,IHC-F,Costim,Block
UniProt
View information about CD28 on UniProt.org

Related FAQs

There are no FAQs for this product.
Go To Top Version: 1    Revision Date: 11-30-2012

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account